Kazia Therapeutics Ltd ADR
NASDAQ: KZIA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John Friend
- Employees
- 6
- Headquarters
- Sydney, Australia
- IPO year
- 1999
- Market cap
- $23.7M
- Website
- https://www.kaziatherapeutics.com
Loading KZIA…
Loading profile data…Frequently asked questions about KZIA
What does Kazia Therapeutics Ltd ADR (KZIA) do?
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical...
Where does KZIA trade?
Kazia Therapeutics Ltd ADR (KZIA) trades on the NASDAQ.
What sector is KZIA in?
Kazia Therapeutics Ltd ADR (KZIA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Kazia Therapeutics Ltd ADR?
John Friend is the chief executive officer of Kazia Therapeutics Ltd ADR (KZIA).
Where is Kazia Therapeutics Ltd ADR headquartered?
Kazia Therapeutics Ltd ADR is headquartered in Australia.
Does KZIA pay a dividend?
Kazia Therapeutics Ltd ADR (KZIA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KZIA go public?
Kazia Therapeutics Ltd ADR (KZIA) completed its initial public offering in 1999.